Journal Information
Vol. 30. Issue 6.
Pages 278-281 (June - July 1994)
Share
Share
Download PDF
More article options
Vol. 30. Issue 6.
Pages 278-281 (June - July 1994)
Full text access
Comparación de la rapidez de acción de terbutalino en inhalador de polvo seco con el aerosol presurizado
Speed of action of dry-powder vs pressurized aerosol terbutaline
Visits
3615
J. Belda Ramírez, P. Casan Clarà, M. González Molina, J. Sanchis Aldás*
Departamento de Neumología. Hospital de la Santa Creu i Sant Pau. Barcelona
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics

En 9 pacientes con obstrucción reversible al flujo aéreo se comparó la rapidez de acción broncodilatadora de terbutalino en polvo, administrado con el sistema Turbuhaler® y la del mismo fármaco, administrado en aerosol líquido por cartucho presurizado. En 2 días consecutivos se administraron 0,5 mg de terbutalino en cartucho presurizado o en Turbuhaler®, realizándose una espirometría basal previa, a los 15, 45 y 90 s y a los 3, 5, 10, 15, 30, 60 y 120 min de la administración del fármaco. Ambas formas de presentación produjeron aproximadamente el 50% de su efecto máximo en los primeros 45 s, alcanzando la media de los incrementos máximos del FEV1, el 80% a los 10 min para el aerosol en polvo y el 83% a los 10 min para el cartucho presurizado; el incremento máximo se alcanzó a los 52 (54) min para el Turbuhaler® y a los 69 (50) min para el cartucho presurizado. El estudio estadístico no reveló diferencias significativas en la rapidez broncodilatadora de ambas formas de presentación. El sistema de administración en polvo del terbutalino (Turbuhaler®) fue tan rápido y eficaz en su respuesta broncodilatadora como el cartucho presurizado de aerosol.

The speed of bronchodilatation with terbutaline administered through the Turbuhaler® system and the same drug administered through a pressurized liquid aerosol device was compared in 9 patients with reversible air flow obstruction. On 2 consecutive days, terbutaline 0.5 mg in aerosol or dry-powder form (Turbuhaler®) was administered after baseline spirometric measurements were taken. Spirometry was repeated at 15, 45 and 90 s and at 3, 5, 10, 15, 30, 60 and 120 min after administration of the drug. Both forms of presentation produced approximately 50% of their maximum effect within the first 45 s; 80% of the patients in the dry-powder group reached the mean of maximum FEV1 increase at 10 min, while 83% in the pressurized-aerosol-device group did so. The maximum increase was reached at 52 (54) min with the Turbuhaler® and at 69 (50) min for the aerosol. The difference in speed of effect for the two pharmaceutical forms were not statistically signiflcant. The administration of terbutaline in powder form (Turbuhaler®) was as fast and effective in achieving bronchodilatation as was the aerosol form.

Full text is only aviable in PDF
Bibliografía
[1.]
E.R. Mc Fadden Jr..
Aerosols.
Inhaled aerosol bronchodilators.,
[2.]
G. Persson, J.E. Wirén.
The bronchodilator response from inhaled terbutaline is influenced by the mass of small particles: a study on a dry powder inhaler (Turbuhaler®).
Eur Respir J, 2 (1989), pp. 253-256
[3.]
S.P. Newman, F. Morén, E. Trofast, N. Talaee, S.W. Clarke.
Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler.
Eur Respir J, 2 (1989), pp. 247-252
[4.]
M. Vidgren, P. Paronen, P. Vidgren, P. Vainio, J. Nuutinen.
In vivo evaluation of the new multiple dose powder inhaler and the Rotahaler using the gamma scintigraphy [resumen].
Acta Pharm Nord, 2 (1990), pp. 3-10
[5.]
J. Sanchis, P. Casan, J. Castillo, et al.
Normativa para la práctica de la espirometría forzada.
Arch Bronconeumol, 25 (1985), pp. 132-142
[6.]
H. Ahlstrom, E. Svenonius, M. Svensson.
Treatment of asthma in pre-school children with inhalation of terbutaline in Turbuhaler compared with Nebuhaler.
Allergy, 44 (1989), pp. 515-518
[7.]
C. Hultquist, H. Ahlstrom, N.I. Kjellman, L.A. Malmqvist, E. Svenonius, S. Melin.
A double-blind comparison between a new multidose powder inhaler (Turbuhaler) and metered dose inhaler in children with asthma.
Allergy, 44 (1989), pp. 467-470
[8.]
G. Fuglsang, S. Pedersen.
Comparison of a new multidose powder inhaler with a pressurized aerosol in children with asthma.
Pediatr Pulmonol, 7 (1989), pp. 112-115
[9.]
K. Osterman, A.M. Norborg, E. Stahl.
A multiple dose powder inhaler (Turbuhaler) compared with a conventional aerosol.
An acceptance study in asthmatics. Allergy, 44 (1989), pp. 294-297
[10.]
K. Wetterlin.
Turbuhaler: a new powder inhaler for administration of drugs to the airways.
Pharm Res, 5 (1988), pp. 506-508
[11.]
G. Persson, E. Gruvstad, E. Sthal.
A new multiple dose powder inhaler (Turbuhaler), compared with a pressurized inhaler in a study of terbutaline in asthmatics.
Eur Respir J, 1 (1988), pp. 681684
[12.]
C.R. Johnsen, E.R. Weeke.
Turbuhaler a new device for dry powder terbutaline inhalation.
Allergy, 43 (1988), pp. 392-395
[13.]
B.M. Zainudin, M. Biddiscombe, S.E. Tolfree, M. Short, S.G. Spiro.
Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution.
Thorax, 45 (1990), pp. 469-473
[14.]
R. Mutterlein, G. Schmidt, W. Fleischer, E. Freund.
A new inhalation system for bronchodilatation. Study of the acceptance of the Ingelheim M inhaler in chronic obstructive respiratory tract diseases [resumen].
Fortschr Med, 108 (1990), pp. 225-228
[15.]
M. Deenstra, P. Zanen, C.F. Gusdorf.
Bronchospasmolytic effects of salbutamol as powder inhalation in patients with reversible bronchial obstruction [resumen].
Arzneimittelforschung, 38 (1988), pp. 1.490-1.491
[16.]
G.M. Pover, C.G. Langdon, S.R. Jones, C. Fidler.
Evaluation of a breath operated powder inhaler.
J Int Med Res, 16 (1988), pp. 201-203
[17.]
F. Gimeno, R. Van Veenen, W.C. Berg, E.J. Steenhuis.
A placebocontrolled comparison between the bronchodilatory effects of ipratropium bromide inhaled as a dry powder and by metered dose inhaler in chronic obstructive pulmonary disease.
Ann Allergy, 61 (1988), pp. 341-343
[18.]
J. Pierce, A.R. Rubinfeld.
Aerosol delivery in lung disease.
Med J Aust, 153 (1990), pp. 357-359
[19.]
T. Engel, J.H. Heinig, F. Madsen, K. Nikander.
Peak inspiratory flow and inspiratory vital capacity of patients with asthma measured with and without a new dry-powder inhaler device (Turbuhaler).
Eur Respir J, 3 (1990), pp. 1.037-1.041
[20.]
S. Pedersen, O.R. Hansen, G. Fuglsang.
Influence of inspiratory flow rate upon the effect of a Turbuhaler.
Arch Dis Child, 65 (1990), pp. 308-310
[21.]
N.E. Eriksson, S.B. Lindgren.
The rapidity of bronchodilation. A comparison of isoprenaline, terbutaline and rimiterol.
Scand J Resp Dis, 59 (1978), pp. 30-36
[22.]
B.J. Sobol, A. Reed.
The rapidity of onset of bronchodilation. A comparison of alupent and isoproterenol.
Ann Allergy, 32 (1974), pp. 137-140
[23.]
P. Casan, R. Miralda, J. Sanchis.
Rapidez de broncodilatación del fenoterol en aerosol.
Arch Bronconeumol, 25 (1989), pp. 259-261
Copyright © 1994. Sociedad Española de Neumología y Cirugía Torácica